BIOLASE, Inc.
BIOLQ
$0.0078
$0.00034.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.65% | -19.12% | -3.21% | -3.99% | -9.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.65% | -19.12% | -3.21% | -3.99% | -9.07% |
| Cost of Revenue | -9.85% | -14.96% | -4.70% | -4.68% | -24.99% |
| Gross Profit | 16.98% | -24.66% | -0.03% | -2.00% | 53.21% |
| SG&A Expenses | -31.59% | -20.92% | -7.09% | -30.07% | -25.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.02% | -18.63% | -6.99% | -17.40% | -25.65% |
| Operating Income | 81.20% | 16.84% | 14.46% | 39.77% | 51.68% |
| Income Before Tax | 69.04% | 42.57% | -10.57% | 45.36% | 45.57% |
| Income Tax Expenses | -20.00% | -35.48% | 1,800.00% | -117.44% | 188.24% |
| Earnings from Continuing Operations | 68.88% | 42.52% | -10.87% | 45.99% | 45.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.88% | 42.52% | -10.87% | 45.99% | 45.28% |
| EBIT | 81.20% | 16.84% | 14.46% | 39.77% | 51.68% |
| EBITDA | 98.41% | -4.98% | 24.82% | 46.85% | 58.33% |
| EPS Basic | 99.64% | 99.68% | 98.36% | 94.24% | 90.62% |
| Normalized Basic EPS | 98.99% | 99.06% | 98.37% | 98.61% | 96.49% |
| EPS Diluted | 99.64% | 99.68% | 98.36% | 94.24% | 90.62% |
| Normalized Diluted EPS | 98.99% | 99.06% | 98.37% | 98.61% | 96.49% |
| Average Basic Shares Outstanding | 2,960.47% | 6,026.79% | 6,676.30% | 3,826.17% | 1,451.32% |
| Average Diluted Shares Outstanding | 2,960.47% | 6,026.79% | 6,676.30% | 3,826.17% | 1,451.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
